Alla Arzumanyan received her Ph.D. in Biotechnology from Yerevan State University (YSU) in Armenia (2003). She then pursued postdoctoral training at Temple University and Thomas Jefferson University in Philadelphia, PA. In 2008 she came to Dr. Feitelson’s group and is currently a Research Associate Professor. She has worked on the pathogenesis of hepatitis B, on the impact of microbial metabolites on the pathogenesis of psoriasis, and is developing an artificial immune system to diagnose, and possibly treat serious human pathogens. She is Chief Development Officer for SFA Therapeutics and has been instrumental in developing a nontoxic, oral therapeutic from selected gut bacteria that is highly effective for the treatment of plaque psoriasis. She has coauthored 17 original papers, 3 book chapters, and has presented 17 posters/invited talks.